---
title: "Tinlarebant (LBS-008) in Stargardt disease type 1: Product information and disease description"
description: "Formulary evidence on Tinlarebant (LBS-008) in Stargardt disease type 1: Product information and disease description. Covers Product description and Place of product in therapy. 63 evidence topics quoted from 51 sources."
canonical: "https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tinlarebant (LBS-008) in Stargardt disease type 1: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Product, sponsor, indication, and FDA orphan status: designation and approval status

| Field | Source quotation |
| --- | --- |
| Orphan designation | “Treatment of Stargardt disease” |
| Date designated | “09/19/2017” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |

Source: [FDA Orphan Drug Designations and Approvals (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=601217)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; NDA submitted June 2026

> “SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE)”
> “completion of its rolling submission of a New Drug Application (NDA)”

Source: [Belite Bio NDA rolling submission completion announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us/)

<a id="topic-2.1.1-3"></a>

##### FDA acceptance, review designation, and target action date

> “accepted and granted Priority Review designation”
> “Prescription Drug User Fee Act target action date is February 12, 2027”

Source: [Belite Bio FDA NDA acceptance announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-us-food-and-drug-administration-acceptance)

<a id="topic-2.1.1-4"></a>

##### Launch: Anticipated in March 2027

> “U.S. LAUNCH READINESS”
> “Launch”
> “March 2027”

Source: [Belite Bio Commercial Day (2026)](https://investors.belitebio.com/static-files/5821cd0b-330c-4a61-877c-04009ccc254d)

<a id="topic-2.1.1-5"></a>

##### Additional regulatory designations

> “Breakthrough Therapy Designation”
> “Fast Track and Rare Pediatric Disease Designations in the U.S.”
> “Orphan Drug Designation in the U.S., Europe, and Japan”

Source: [Belite Bio FDA Breakthrough Therapy designation announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-fda-granting-breakthrough-therapy)

<a id="topic-2.1.1-6"></a>

##### Japan: regulatory submission and expedited review

> “submission of a New Drug Application (NDA)”
> “Tinlarebant has been designated a SAKIGAKE pharmaceutical product for accelerated review”

Source: [Belite Bio Japan NDA submission announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-submission-new-drug-application-ministry)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Product, sponsor, indication, and FDA orphan status: product and sponsor

| Field | Source quotation |
| --- | --- |
| Generic name | “tinlarebant” |
| Sponsor | “Belite Bio, LLC” |

Source: [FDA Orphan Drug Designations and Approvals (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=601217)

<a id="topic-2.1.2.1-2"></a>

###### Names, drug class, and proposed mechanism of action: names and class

> “Tinlarebant, or LBS-008”
> “Tinlarebant is a potent, orally administered small molecule RBP4 antagonist”

Source: [Belite Bio](https://belitebio.com/product-008/)

<a id="topic-2.1.2.1-3"></a>

###### Manufacturer: Belite Bio

> “Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye.”

Source: [Belite Bio NDA rolling submission completion announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us/)

Additional sources: [Vaccaro et al. (2023)](https://access.portico.org/Portico/show?auId=pjbdch1zk14&viewFile=pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational dosage form

> “orally administered tablet”

Source: [Belite Bio (2024)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-presents-additional-analysis-phase-2-study/)

Additional sources: [Selleck Chemicals](https://www.selleckchem.com/msds/MSDS_E6681_eu.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Investigational indication: orphan designation

> “Treatment of Stargardt disease”

Source: [FDA Orphan Drug Designations and Approvals (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=601217)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Names, drug class, and proposed mechanism of action: retinol delivery

> “reduce the delivery of retinol to the eye”

Source: [Belite Bio](https://belitebio.com/product-008/)

Additional sources: [Cioffi (2025)](https://acs.digitellinc.com/live/35/session/563555)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Phase 1b/2: RBP4 reduction

> “Tinlarebant (5 mg/day, p.o.) produces a sustained mean RBP4 reduction of ~80%.”

Source: [ARVO Annual Meeting (2023)](https://investors.belitebio.com/static-files/a5527853-be5e-49c4-a007-c84e2850e85a)

Additional sources: [Grigg et al. (2024)](https://iovs.arvojournals.org/article.aspx?articleid=2797066)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics and drug interactions

> “healthy adults”
> “5 mg single dose”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-2.1.2.6.3-2"></a>

###### Pharmacokinetics and drug interactions: food

> “Cmax and AUCinf ratios”
> “1.08–1.22”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Adolescents and young adults: studied age range

> “12 to 20 years old”

Source: [Belite Bio second quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-second-quarter-2026-financial)

<a id="topic-2.1.2.8-2"></a>

###### Hepatic and renal impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Tinlarebant

<a id="topic-2.1.2.9.1-1"></a>

###### Pharmacokinetics and drug interactions: coadministration

| Coadministration | “Cmax ratio” | “AUCinf ratio” |
| ---------------- | -----------: | -------------: |
| “omeprazole”     |       “1.16” |         “1.03” |
| “itraconazole”   |       “1.29” |         “2.42” |
| “Rifampin”       |       “0.53” |         “0.19” |

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-2.1.2.9.1-2"></a>

###### Publication recommendation concerning CYP3A inducers: not approved labeling

> “contraindicated with strong CYP3A inducers”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="topic-2.1.2.9.1-3"></a>

###### Investigator conclusion on coadministration and food

> “These data show that the pharmacokinetics of tinlarebant is not significantly altered by gastric acid suppression or food.”
> “Dosing patients with tinlarebant and strong CYP3A inhibitors concurrently is unlikely to compromise safety based on its pharmacokinetic–pharmacodynamic relationships, but tinlarebant should be contraindicated with strong CYP3A inducers due to the risk of treatment failure.”
> “No unexpected safety signals occurred and tinlarebant was well tolerated in all participants.”

Source: [Polasek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41545331/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Tinlarebant on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### DRAGON: investigational dose

> “5mg of tinlarebant or matching placebo.”

Source: [UK Health Research Authority (2021)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-of-tinlarebant-as-treatment-for-adolescent-stargardt-disease/)

Additional sources: [ClinicalTrials.gov NCT05244304](https://clinicaltrials.gov/study/NCT05244304)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### DRAGON: administration

> “The study drug will be taken orally once per day.”

Source: [UK Health Research Authority (2021)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-of-tinlarebant-as-treatment-for-adolescent-stargardt-disease/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Anticipated distribution and patient support

> “Specialty Pharmacy”
> “Prescription routed for fulfillment”
> “Onboarding into support programs”

Source: [Belite Bio Commercial Day (2026)](https://investors.belitebio.com/static-files/5821cd0b-330c-4a61-877c-04009ccc254d)

<a id="topic-2.1.2.11-2"></a>

###### Anticipated patient financial support

> “Financial Support Programs for Eligible Patients”

Source: [Belite Bio Commercial Day (2026)](https://investors.belitebio.com/static-files/5821cd0b-330c-4a61-877c-04009ccc254d)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Tinlarebant on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

Additional sources: [Kay et al. (2026)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2853582); [Palmgren et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/17469899.2026.2645188); [Fujinami et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37940365/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Inherited retinal disease

> “Stargardt disease is a rare genetic eye disease”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="topic-2.2.1.1-2"></a>

###### ABCA4 and vitamin A handling

> “Stargardt disease is usually caused by changes in a gene called ABCA4. This gene affects how your body uses vitamin A.”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

Additional sources: [MedlinePlus Genetics](https://medlineplus.gov/genetics/condition/stargardt-macular-degeneration/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Stargardt disease type 1

<a id="topic-2.2.1.2.1-1"></a>

###### Incidence and prevalence: Netherlands nationwide registry: incidence

> “The incidence was 1.67‐1.95:1,000,000 per year”
> “with and without 10% of potentially unregistered cases”

Source: [Runhart et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9291619/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Stargardt disease type 1

<a id="topic-2.2.1.2.2-1"></a>

###### Estimated U.S. patient population

> “STGD1 affects an estimated 53,000 people in the U.S. alone”

Source: [Belite Bio NDA rolling submission completion announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us/)

<a id="topic-2.2.1.2.2-2"></a>

###### Incidence and prevalence: Netherlands nationwide registry: prevalence

> “point prevalence in 2018 was approximately 1:22,000‐1:19,000”
> “with and without 10% of potentially unregistered cases”

Source: [Runhart et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9291619/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Clinical course and visual prognosis: variability

> “The rate at which vision is lost varies for each person.”

Source: [UCSF Health](https://www.ucsfhealth.org/care/conditions/stargardt-disease)

<a id="topic-2.2.1.3-2"></a>

###### ProgStar report no. 10: visual acuity change over 24 months

> “Visual Acuity Change Over 24 Months”
> “Overall, BCVA declined at a rate of 0.011 logMAR per year (−0.55 letters/y)”

Source: [Kong et al. (2018)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2684573)

<a id="topic-2.2.1.3-3"></a>

###### ProgStar report no. 17: progression of definitely decreased autofluorescence

> “The overall estimated progression of DDAF was 0.74 mm²/y (95% CI 0.64-0.85, P < .0001)”

Source: [Strauss et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36764427/)

<a id="topic-2.2.1.3-4"></a>

###### Age at onset and prognosis by onset age

> “Patients with Stargardt disease demonstrate a progressive impairment of visual acuity (VA), which often begins within the first or second decades of life; however, both early and later adult-onset Stargardt disease also are observed, with later onset being associated with a better prognosis.”

Source: [Strauss et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26786511/)

<a id="topic-2.2.1.3-5"></a>

###### ProgStar report no. 1: baseline disease severity in the natural history cohorts

> “Three hundred sixty-five unique patients aged 6 years and older at baseline harboring disease-causing variants in the ABCA4 gene and with specified ocular lesions were enrolled from 9 centers in the United States and Europe.”
> “At baseline, 36% had no or mild VA loss, and 47% of the study eyes had areas of definitely decreased autofluorescence (DDAF) with an average lesion area of 2.5±2.9 mm² (range, 0.02–16.03 mm²).”
> “At baseline, 20% had no or mild VA loss, and 64% had areas of DDAF with an average lesion area of 4.0±4.4 mm² (range, 0.03–24.24 mm²).”
> “The ProgStar cohorts have baseline characteristics that encompass a wide range of disease severity and are expected to provide valuable data on progression based on serial quantitative measurements derived from multiple methods, which will be critical to the design of planned clinical trials.”

Source: [Strauss et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26786511/)

Additional sources: [Ibukun et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41773771/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Bisretinoids and early photoreceptor pathology: review

> “Bisretinoids as a Source of Early Photoreceptor Pathology in Stargardt Disease”
> “formation and accumulation of bisretinoids begin within photoreceptors”

Source: [Mata et al. (2025)](https://karger.com/ore/article/68/1/555/938764/Bisretinoids-as-a-Source-of-Early-Photoreceptor)

Additional sources: [Dayma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12295471/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Anticipated diagnostic testing

> “ABCA4 Test”
> “Confirmatory test expected”

Source: [Belite Bio Commercial Day (2026)](https://investors.belitebio.com/static-files/5821cd0b-330c-4a61-877c-04009ccc254d)

<a id="topic-2.2.1.5-2"></a>

###### Clinical and molecular diagnostic assessment

> “Dilated eye exam, photos or scans of the retina, genetic testing”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="topic-2.2.1.5-3"></a>

###### ABCA4-associated disease in childhood and adolescence

> “ABCA4-associated disease in childhood and adolescence”
> “Only four patients revealed a definitely decreased autofluorescence in the macula.”

Source: [Bodenbender et al. (2025)](https://link.springer.com/article/10.1007/s00417-025-06884-9)

<a id="topic-2.2.1.5-4"></a>

###### Mesopic microperimetry in Stargardt disease: application and reliability

> “Mesopic microperimetry in Stargardt disease: Application and reliability”
> “Mesopic microperimetry (mMP) is a promising functional endpoint in clinical trials for Stargardt disease type 1 (STGD1).”

Source: [Kootstra et al. (2026)](https://www.ovid.com/journals/acoph/fulltext/10.1111/aos.70072~mesopic-microperimetry-in-stargardt-disease-application-and)

Additional sources: [American Academy of Ophthalmology (2022)](https://www.aao.org/education/clinical-statement/guidelines-on-clinical-assessment-of-patients-with)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Central vision: progressive visual loss

> “The most common symptom of Stargardt disease is a slow loss of central vision in both eyes.”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="topic-2.2.1.6-2"></a>

###### Central vision: scotomas

> “Gray, black, or hazy spots in the center of your vision”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="topic-2.2.1.6-3"></a>

###### Light sensitivity and adaptation

> “Sensitivity to light”
> “Needing more time for your eyes to adjust between light and dark places”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Clinical course and visual prognosis: long-term acuity

> “most people with Stargardt disease have 20/200 to 20/400 vision”

Source: [UCSF Health](https://www.ucsfhealth.org/care/conditions/stargardt-disease)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Stargardt disease type 1

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Vision-specific quality of life and functional vision: Brazil

> “41 patients with STGD and 46 healthy volunteers”
> “Individuals with STGD had significant impairment of vision-specific QoL and functional vision compared with controls”

Source: [Gomes et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35975566/)

<a id="topic-2.2.1.8.1-2"></a>

###### Mental health outcomes in inherited retinal diseases: Stargardt disease subgroup

> “only two studies encompassing 75 participants”

Source: [Abu Serhan et al. (2026)](https://link.springer.com/article/10.1186/s40942-026-00820-7)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient-reported outcome measures in recessive Stargardt disease

> “Properties of Patient-Reported Outcome Measures in Recessive Stargardt Disease”
> “The NEI VFQ and IVI have acceptable psychometric properties in STGD1”

Source: [Terheyden et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36130585/)

<a id="topic-2.2.1.8.1-4"></a>

###### Daily functioning, independence, and caregivers: daily functioning

> “lose the ability to read, drive, and recognize faces, leading to difficulty in school, work, social situations, and loss of independence.”

Source: [Stargardt disease patient-listening-session report (2022)](https://www.fda.gov/media/165186/download)

Additional sources: [Hoang et al. (2026)](https://iovs.arvojournals.org/article.aspx?articleid=2811812); [Roborel de Climens et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33305649/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Direct healthcare costs: U.S. outpatient claims

> “Outpatient administrative claims data (2010–2014)”
> “The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71)”

Source: [Aziz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11207193/)

<a id="topic-2.2.1.8.2-2"></a>

###### Cost-of-illness studies of inherited retinal diseases: systematic review

> “Cost-of-illness studies of inherited retinal diseases: a systematic review”
> “non-health costs constituted the overwhelming majority of costs (87 to 98%)”

Source: [Ng et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03099-9)

Additional sources: [Gong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257071/); [Knott et al. (2023)](https://www.valueinhealthjournal.com/article/S1098-3015%2823%2904098-6/fulltext)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Stargardt disease type 1 on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Daily functioning, independence, and caregivers: caregiver needs

> “Caregivers are necessary”

Source: [Stargardt disease patient-listening-session report (2022)](https://www.fda.gov/media/165186/download)

<a id="topic-2.2.1.8.3-2"></a>

###### Patient testimony: costs of assistive technology

> “Uses technology to assist with vision loss, but it’s expensive, quickly becomes obsolete, and is not sustainable for most people.”

Source: [Stargardt disease patient-listening-session report (2022)](https://www.fda.gov/media/165186/download)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### South Africa: time-limited 2025 genetic-testing offer

> “A total fee of R6000 will cover your DNA testing”
> “but only until August 2025.”

Source: [Retina South Africa (2025)](https://retinasa.org.za/hope-on-the-horizon-for-stargardt-disease/)

<a id="topic-2.2.1.8.4-2"></a>

###### South Africa: additional genetic-counseling consultation cost

> “(± R1600, often covered by medical aids).”

Source: [Retina South Africa (2025)](https://retinasa.org.za/hope-on-the-horizon-for-stargardt-disease/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Low-vision Aids and Vision Rehabilitation

<a id="topic-2.2.2.1.1-1"></a>

###### Stargardt disease: patient-care guidance: low-vision care

> “Vision aids, vision rehabilitation”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="topic-2.2.2.1.1-2"></a>

###### Management of ABCA4 retinopathy: review

> “Update on the Management of ABCA4 Retinopathy (Stargardt Disease)”
> “Supportive care remains a foundational component in the management of ABCA4 retinopathy”

Source: [Parameswarappa et al. (2026)](https://link.springer.com/article/10.1007/s40123-026-01407-z)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Lifestyle and Light-exposure Management

<a id="topic-2.2.2.1.2-1"></a>

###### Stargardt disease: patient-care guidance: vitamin A supplementation

> “Don’t take dietary supplements with more than the daily recommended amount of vitamin A.”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="topic-2.2.2.1.2-2"></a>

###### Sunlight protection

> “Wear a hat and sunglasses to protect your eyes from sunlight when you go outside.”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

Additional sources: [Federspiel et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29939824/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Genetic Counseling

<a id="topic-2.2.2.1.3-1"></a>

###### Genetic counseling and family planning

> “visit a genetic counselor who can discuss disease inheritance and help with family planning, career choices”

Source: [UCSF Health](https://www.ucsfhealth.org/care/conditions/stargardt-disease)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Limitations of Current Therapies

<a id="topic-2.2.2.1.4-1"></a>

###### Summary

Current care includes low-vision aids, vision rehabilitation, and measures to limit avoidable retinal stress. The National Eye Institute describes no treatment for Stargardt disease, while the 2026 management review identifies supportive care as foundational. The 2018 technology assessment reported limitations in the size, duration, and quality of studies available at that time; it predates the completed DRAGON trial.

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease); [Parameswarappa et al. (2026)](https://link.springer.com/article/10.1007/s40123-026-01407-z); [Waugh et al. (2018)](https://www.ncbi.nlm.nih.gov/books/NBK500486/?report=reader); [Belite Bio first quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-first-quarter-2026-financial/)

<a id="topic-2.2.2.1.4-2"></a>

###### Unmet treatment need

> “There’s no treatment for Stargardt disease”

Source: [National Eye Institute (2024)](https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/stargardt-disease)

<a id="topic-2.2.2.1.4-3"></a>

###### Treatments for dry age-related macular degeneration and Stargardt disease

> “Overall, there were disappointingly few good-quality studies (including of sufficient size and duration) reporting useful outcomes, particularly in STGD.”

Source: [Waugh et al. (2018)](https://www.ncbi.nlm.nih.gov/books/NBK500486/?report=reader)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Tinlarebant is being developed as an oral treatment for Stargardt disease type 1. DRAGON studied participants aged 12–20 years with established atrophic lesions and visual acuity of 20/200 or better. This trial population should not be equated with a finalized approved population. The sponsor anticipates confirmatory ABCA4 testing, specialty-pharmacy fulfillment, and patient-support programs. These are proposed access arrangements rather than an approved care pathway.

Source: [Belite Bio](https://belitebio.com/product-008/); [Belite Bio first quarter 2026 results announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-reports-unaudited-first-quarter-2026-financial/); [Edwards et al. (2026)](https://onlinelibrary.wiley.com/doi/10.1111/ceo.70050); [Belite Bio Commercial Day (2026)](https://investors.belitebio.com/static-files/5821cd0b-330c-4a61-877c-04009ccc254d); [Belite Bio FDA NDA acceptance announcement (2026)](https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-us-food-and-drug-administration-acceptance); [FDA Orphan Drug Designations and Approvals (2017)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=601217)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

No evidence found.

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Stargardt’s Connected Research Network inaugural meeting report

> “Increase access to comprehensive genetic testing globally, ensuring equitable participation across different regions and populations.”

Source: [Britten-Jones et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449819/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### DRAGON: reported reduction in DDAF lesion growth versus placebo

> “35.7%”

Source: [Belite Bio DRAGON topline results announcement (2025)](https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite/)

## Related pages
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Terms and abbreviations](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations.md)
- [Tinlarebant (LBS-008): Stargardt disease type 1](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/executive-summary.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Clinical evidence](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: Economic information and modeling report](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economics.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: References](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: prevalence by geography](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/prevalence.md)
- [Tinlarebant (LBS-008) in Stargardt disease type 1: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/cost-effectiveness-analyses.md)
